Syros Pharmaceuticals, Inc. Syros Pharmaceuticals, Inc.
  • Home
  • Our Coordinated Expression
    • Overview
    • Our Culture, Mission & Values
    • Our Commitment to Diversity, Equity & Inclusion
    • Message from BIO
  • Our People
    • Overview
    • Leadership
    • Board of Directors
    • Founders
  • Programs
    • Overview
    • Tamibarotene
    • SY-2101
    • SY-5609
    • Expanded Access Policy
  • Platform
    • Overview
    • What is Gene Control?
    • Publications and Abstracts
  • Patients
  • Investors & Media
  • Partners
  • Careers
  • Blog
  • Contact
Investors & Media

Investors & Media

  • Overview
  • News
    • Email Alerts
    • Press Releases
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Company Info
    • Profile
    • Leadership
    • Contacts
    • Analyst Coverage
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
    • IRS Tax Form 8937
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Filings
    • Quarterly Reports
    • Proxy
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor & Media Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Press Releases

  • News

  • Email Alerts
  • Press Releases
Nov 22, 2022

Syros to Participate at Piper Sandler 34th Annual Healthcare Conference

Nov 14, 2022

Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022

Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Nov 4, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 3, 2022

Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting

Oct 5, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 16, 2022

Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement

Sep 15, 2022

Syros and Tyme Technologies Announce Stockholder Approval of Merger

Sep 13, 2022

Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer

Sep 7, 2022

Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference

RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...27
    © 2023 Syros Pharmaceuticals, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Sitemap
    twitter logo linkedin logo